EBs ranked on healthcare/biopharma prestige?
Have an offer from two EBs on their healthcare teams and was wondering what the general consensus is on the street in terms of the clout EBs have with healthcare/biopharma
Trending Content
Career Resources
Centerview/jpm are hands down the leaders in the healthcare space. JPMs healthcare conference is on par with Allen & co’s TMT sun valley conference.
Moelis and PWP healthcare are killing it in the bio pharma/med tech space. These two teams have been growing rapidly and have closed some really interesting and large deals. MoCo’s $12 billion deal with thermo fisher and PWP’s $12 billion deal with baxter come to mind.
Lazard and Evercore would follow Moelis/PWP. A lot more mature, each having solid relationships with huge biotech companies (i.e Lazard and Gilead).
William Blair/SVB L also come to mind but are not as prestigious as above.
CVP/JPM > Moelis/PWP > Lazard/EVR > WB/SVB
This. Friend of mine is a client at JPM I believe and loves their HC conference.
This is good Info ^^
How can u put Moe/PWP over EVR? Isn’t EVR really good, like right behind CVP in the EB HC space out west?
You got it
CVP > Lazard/Moelis > EVR/PWP
Moelis is not even in the discussion. Most of their team quit. Total sweatshop
Hi! Mind if I DM for some questions… currently deciding between some of those banks for my SA internship.
Hard disagree, they’re a growing group at Moelis and PWP and have closed really big deals.
I would consider breaking it out by M&A and Cap Markets. For EBs, Centerview and Lazard are definitely at the top for M&A; no one will ever be able to compete with Mark Robinson’s team on the west coast. Evercore does a decent amount of capital markets, but they haven’t had as strong of a M&A presence.
Not sure where Moelis is coming from - they recently split out the life sciences team, but I’ve never heard anything positive about their healthcare practice in general.
For group reputation
1. Centerview is great for M&A. Mark Robinson is one of the top bankers in Wall Street
2. Evercore/Lazard are both good for M&A. They are involved in many relevant deals each year and across sizes. Evercore might be more interesting since they have a capital markets desk and are involved in more types of conversations
3. Guggenheim, for similar reasons. Just slightly smaller volume.
**drop off**
4. PJT/Moelis/PWP - they get on deals, but very inconsistent. I honestly couldn’t split this group out but perhaps there’s a distinction
Source: I work in HC banking
Views on Gugg and boutiques like Cain/MTS?
Does CVR have a specialized healthcare group? Somewhere on this forum, I had read that all analysts / associates are generalists - I could be mistaken though. Seems hard to understand how they could have generalists functioning in a highly-specialized life sciences sector
this is more like it. lmao at the ppl earlier placing moelis and PWP above EVR and Laz
Quos consectetur suscipit eius autem ipsam. Aut tenetur ullam quidem qui est voluptatibus. Perspiciatis eum voluptas ut repellat cumque dolores.
Non ut velit tenetur debitis consequuntur. Voluptatum omnis id esse voluptatibus. Voluptas ratione placeat voluptas et ea quia doloremque. Illo aliquam omnis nobis error pariatur accusantium doloremque ducimus. Modi ad quo sit amet. Aliquid aut id voluptas quae natus cum corporis. Unde consequuntur autem consequatur consequatur aut.
Inventore sit nostrum quis magni facere distinctio nobis. Aut odit sit aut placeat. In sit voluptatem tempore quia.
Repudiandae perspiciatis nihil ducimus omnis sapiente voluptatem eaque. Pariatur adipisci vitae porro doloribus ipsa molestiae. Hic sunt dolorum autem.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...